Xeris Biopharma’s (XERS) “Neutral” Rating Reiterated at Piper Sandler
Piper Sandler reaffirmed their neutral rating on shares of Xeris Biopharma (NASDAQ:XERS – Free Report) in a research report released on Friday,Benzinga reports. They currently have a $4.00 target price on the stock, up from their previous target price of $3.00. A number of other brokerages have also recently issued reports on XERS. Jefferies Financial […]
Piper Sandler reaffirmed their neutral rating on shares of Xeris Biopharma (NASDAQ:XERS – Free Report) in a research report released on Friday,Benzinga reports. They currently have a $4.00 target price on the stock, up from their previous target price of $3.00. A number of other brokerages have also recently issued reports on XERS. Jefferies Financial […]
